EUVIMEDEUVIMED entdecken
Crossref

CAR T cell–derived TNF is an early determinant of cytokine release syndrome severity

Pieter L Lindenbergh iD, Theodoros Giavridis iD, Ophélie Vivier iD, Michael A Lopez iD, Anton Dobrin iD, Matthias Mack iD, José L Cohen iD, Maria Themeli iD, Michel Sadelain iD

Science Immunology · 21.08.2026 · 11 (122)

DOI: 10.1126/sciimmunol.aea6276 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Immunology, erschienen am 21.08.2026. Verfasst von Pieter L Lindenbergh und 8 weiteren Autor:innen. Beteiligte Einrichtung: Columbia Institute for Cell Engineering and Therapy (CICET), Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, N…. Hauptthemen laut MEDLINE: Tumor Necrosis Factor-alpha, Cytokine Release Syndrome, Receptors, Chimeric Antigen, T-Lymphocytes. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 91 Literaturangaben. Gefördert von: National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cytokine release syndrome (CRS) is a common and potentially severe toxicity of chimeric antigen receptor (CAR) T cell therapy, characterized by activation of the host myeloid compartment and systemic inflammation. Although downstream effectors such as interleukin-6 (IL-6) and IL-1β are well-characterized, the upstream signals that initiate CRS remain incompletely understood. By selectively disrupting tumor necrosis factor (TNF) signaling in a mouse model of CRS, we show that CAR T cell–derived TNF promotes the accumulation of pro-inflammatory monocyte-derived macrophages at the tumor site and the induction of host-derived cytokines including IL-6 and IL-1β. We further show that TNF is a determinant of CRS severity in humanized xenochimeras, governing the overall disease course including eventual lethality. Our findings thus identify TNF as an upstream regulator of CRS acting at least in part via the host macrophage compartment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tumor Necrosis Factor-alphaCytokine Release SyndromeReceptors, Chimeric AntigenT-LymphocytesImmunotherapy, AdoptiveAnimalsMiceMacrophagesHumansInterleukin-1beta

Substanzen

Tumor Necrosis Factor-alphaReceptors, Chimeric AntigenInterleukin-1beta

Autor:innen und Institutionen

  • Columbia Institute for Cell Engineering and Therapy (CICET), Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, USA.
  • Department of Hematology, Cancer Center Amsterdam, Amsterdam UMC, Amsterdam, Netherlands.
  • OverT Bio, New York, NY, USA.
  • Université Paris Est Créteil, Créteil, France.
  • Department of Biological Sciences, Sunnybrook Research Institute, Toronto, Canada.
  • Department of Nephrology, University Hospital Regensburg, Regensburg, Germany.

ORCID-Profile: Pieter L Lindenbergh, Theodoros Giavridis, Ophélie Vivier, Michael A Lopez, Anton Dobrin, Matthias Mack, José L Cohen, Maria Themeli, Michel Sadelain

Förderung

  • National Cancer Institute

Zitieren

APA

Lindenbergh, P. L., Giavridis, T., Vivier, O., Lopez, M. A., Dobrin, A., Mack, M., Cohen, J. L., Themeli, M., & Sadelain, M. (2026). CAR T cell–derived TNF is an early determinant of cytokine release syndrome severity. Science Immunology, 11(122). https://doi.org/10.1126/sciimmunol.aea6276

Vancouver

Lindenbergh PL, Giavridis T, Vivier O, Lopez MA, Dobrin A, Mack M, et al. CAR T cell–derived TNF is an early determinant of cytokine release syndrome severity. Science Immunology. 2026;11(122). doi:10.1126/sciimmunol.aea6276

BibTeX
@article{Lindenbergh2026,
  author = {Lindenbergh, Pieter L and Giavridis, Theodoros and Vivier, Ophélie and Lopez, Michael A and Dobrin, Anton and Mack, Matthias and Cohen, José L and Themeli, Maria and Sadelain, Michel},
  title = {CAR T cell–derived TNF is an early determinant of cytokine release syndrome severity},
  journal = {Science Immunology},
  year = {2026},
  volume = {11},
  number = {122},
  doi = {10.1126/sciimmunol.aea6276}
}
Kostenlos starten →